Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy

Cancer. 2018 Sep 1;124(17):3586-3595. doi: 10.1002/cncr.31589. Epub 2018 Aug 18.

Abstract

Background: Treatment for advanced lung adenocarcinoma (AC) has become increasingly personalized based on molecular results. However, for patients with AC brain metastases (BMs), intracranial outcomes based on molecular subtype and the frequency of molecular aberrations are less well defined. This study sought to report targeted next-generation sequencing results and investigate molecularly based outcomes for patients with AC-BMs treated with radiotherapy.

Methods: The records of 132 patients with AC-BMs treated at Emory University from September 2008 to August 2016 with successful next-generation sequencing were reviewed. Rates of local disease recurrence, distant brain failure (DBF), and salvage whole-brain radiotherapy (WBRT) were estimated using cumulative incidence with competing risk analysis. Univariate and multivariate analyses were performed.

Results: The most common aberrations included tumor protein 53 (TP53) (60%), KRAS (29%), epidermal growth factor receptor (EGFR) (20.5%), phosphatase and tensin homolog (PTEN) loss (15.5%), and MET amplification (13%). The majority of patients (62%) were treated with stereotactic radiosurgery alone. In these patients, KRAS mutation, anaplastic lymphoma kinase (ALK) rearrangement, and having ≥ 6 BMs were associated with an increased risk of salvage WBRT (P < .05). KRAS mutation remained significant for an increased risk of salvage WBRT when compared with EGFR/ALK/KRAS-negative patients (hazard ratio, 5.17; P < .05), despite a similar risk of DBF. PTEN loss was associated with increased risk of DBF (P < .05), whereas EGFR and ALK aberrations were associated with a decreased risk of local disease recurrence (P < .05).

Conclusions: The results of the current study quantified the frequency of genetic aberrations in patients with AC-BMs and demonstrated their association with intracranial outcomes. In particular, a cohort of patients with KRAS mutations and ≥6 BMs were identified to be at high risk of requiring salvage WBRT after undergoing upfront stereotactic radiosurgery.

Keywords: DNA sequence analysis; adenocarcinoma; brain metastases; distant brain failure; intracranial failure; neoplasm metastases; next-generation sequencing; non-small cell lung cancer; stereotactic radiosurgery; whole-brain radiotherapy.

MeSH terms

  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology*
  • Adenocarcinoma of Lung / radiotherapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • Anaplastic Lymphoma Kinase / genetics
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / radiotherapy*
  • Brain Neoplasms / secondary*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Cranial Irradiation / methods
  • DNA Mutational Analysis
  • ErbB Receptors / genetics
  • Follow-Up Studies
  • Gene Frequency
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / radiotherapy*
  • Middle Aged
  • PTEN Phosphohydrolase / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Radiosurgery
  • Sequence Analysis, DNA / methods
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics

Substances

  • KRAS protein, human
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Proto-Oncogene Proteins p21(ras)